Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,303 total articles
Windacre Partnership LLC, a major 10% shareholder in Perimeter Solutions, Inc. (NASDAQ:PRM), executed a substantial divestiture of its holdings, offloading approximately $195.6 million worth of ordinary shares between June 26 and June 30, 2026. This transaction follows a period of significant price appreciation for PRM, which has seen a 156% gain o…
Sardar Biglari's affiliated entity, Lion Fund II, L.P., executed a series of transactions disposing of approximately $3.7 million in El Pollo Loco Holdings, Inc. stock between June 26 and June 30, 2026. The sales occurred at weighted average prices ranging from $16.58 to $16.91 per share, leaving the fund with a remaining stake of 3,777,400 shares.…
Galectin Therapeutics director Harold H. Shlevin has completed the sale of 30,000 common shares, netting approximately $150,890. The transactions, executed under a Rule 10b5-1 plan, involved the disposal of shares acquired through option exercises. This activity coincides with significant regulatory and clinical developments for the company's lead …
Joan M. Herman, Executive Vice President of Operations and a director at Paysign, Inc. (NASDAQ:PAYS), executed a significant divestment of company equity on June 26, 2026. The transaction involved the sale of 100,000 shares of common stock, generating total proceeds of $801,140. This sale was facilitated through a Rule 10b5-1 trading plan, which He…
Jamil Khurram, Chief Medical Officer at Galectin Therapeutics Inc. (NASDAQ: GALT), executed a series of stock transactions between June 26 and June 29, 2026, under a Rule 10b5-1 trading plan. The executive sold 52,037 shares for $262,083 after acquiring the same number of shares through option exercises valued at $129,481. Following these transacti…
Omada Health, Inc. (NASDAQ: OMDA) Chief Accounting Officer Craig Gracey recently completed a series of stock transactions valued at $85,423, selling a total of 4,167 shares between June 26 and June 29, 2026. The sales were executed under a pre-established 10b5-1 trading plan adopted in March 2026. These transactions occurred during a period of sign…
Steven L. Cook, Chief Financial Officer of Omada Health, Inc. (NASDAQ:OMDA), recently completed a series of share sales totaling $1,034,616 between June 26 and June 29, 2026. The transactions, executed under a 10b5-1 trading plan established in March 2026, spanned a price range of $19.6727 to $21.0678 per share. Following these sales, Cook retains …
Jason P. Rhodes, a director at Dyne Therapeutics, Inc. (NASDAQ:DYN), recently completed the sale of 504,695 shares of the company's common stock, generating approximately $10.7 million in proceeds. The transactions occurred on June 26 and June 29, 2026, with shares sold at prices ranging from $21.14 to $21.28. These sales were executed under a Rule…
Micron Technology Inc. (NASDAQ: MU) President and Chief Executive Officer Sanjay Mehrotra executed a significant stock sale on June 26, 2026, divesting 26,736 shares for a total value of $32,761,315. The transactions, priced between $1,128.41 and $1,169.96 per share, were conducted under a Rule 10b5-1 trading plan established earlier in the year. T…
Micron Technology Inc. (NASDAQ: MU) President and CEO Sanjay Mehrotra sold 11,294 shares of the company's common stock on June 26, 2026, realizing proceeds of $13,573,976. The transactions were executed at prices between $1,170.60 and $1,192.42 per share under a Rule 10b5-1 trading plan established earlier in the year. Following the sale, Mehrotra …
Samira Shaikhly, Septerna’s Chief People Officer, executed a transaction involving the exercise of stock options and the subsequent sale of 2,178 shares, netting $76,622. The move, structured under a Rule 10b5-1 plan adopted in late 2025, occurs against a backdrop of significant stock appreciation and ongoing clinical developments for the company’s…
Jon Congleton, Chief Executive Officer of Mineralys Therapeutics, Inc. (NASDAQ: MLYS), has completed a series of stock transactions totaling approximately $1.96 million. The sales were executed under a Rule 10b5-1 trading plan established in late December 2025. This executive activity occurs against the backdrop of the company's ongoing financial r…
Eric Warren, Chief Commercial Officer at Mineralys Therapeutics, Inc. (NASDAQ: MLYS), recently completed the sale of 104,124 shares of the company's common stock. The transaction, valued at approximately $2,696,322, was carried out on June 26, 2026. This sale was executed under the framework of a pre-arranged Rule 10b5-1 trading plan, which Mr. War…
Susan M. Byrne, serving as Director Emerita at Westwood Holdings Group Inc. (NASDAQ: WHG), has executed a series of stock sales totaling approximately $246,550 during late June. The transactions were carried out under a Rule 10b5-1 trading plan established on April 1, 2026. Following these dispositions, Byrne retains a direct stake of 239,017 share…
Joshua Hug, a director at Remitly Global, Inc. (NASDAQ:RELY), completed a total sale of $764,400 in company shares over two days in late June. The transactions were executed automatically under a Rule 10b5-1 trading plan established in December 2025. This divestment occurs as Remitly's stock price has risen significantly, trading around $22.42, whi…
Kelly Bliss, president of the U.S. Group Health division at Teladoc Health, Inc. (NASDAQ:TDOC), has executed a sale of 2,500 shares of the company's common stock. The transaction, which netted $21,250, was conducted under a Rule 10b5-1 trading plan established in August 2025. This sale takes place as Teladoc Health navigates a period of strategic e…
Rahul Khara, Chief Legal Officer at Disc Medicine, Inc. (NASDAQ:IRON), sold 2,500 shares of common stock for $187,500 in late June 2026. The sales occurred on June 26 and June 29, 2026, at $75.00 per share. These sales followed the acquisition of an equal number of shares through the exercise of stock options at $14.69 per share, totaling $36,725. …
Joseph Baroldi, Executive Vice President and Chief Business Officer at Ionis Pharmaceuticals Inc. (NASDAQ: IONS), disclosed that his spouse executed a series of transactions involving the company’s common stock on June 26, 2026. The spouse sold 5,635 shares through a pre-arranged Rule 10b5-1 trading plan, generating $451,698, while simultaneously a…
Patrick R. O’Neil, Executive Vice President, Chief Legal Officer, and General Counsel at Ionis Pharmaceuticals (NASDAQ: IONS), executed a sale of company stock on June 26, 2026. The transaction, valued at $245,520, involved the disposal of 3,069 shares at a price of $80.00 per share. The sale was conducted pursuant to a Rule 10b5-1 trading plan est…
Eugene Schneider, Executive Vice President and Chief Clinical Development Officer at Ionis Pharmaceuticals Inc. (NASDAQ:IONS), executed a series of transactions on June 26, 2026, involving the sale and acquisition of company stock. The sale, conducted under a Rule 10b5-1 trading plan, resulted in the disposal of 26,000 shares at a weighted average …
Jonathan Yen-Wen Yu, Chief Operating Officer of Disc Medicine, Inc. (NASDAQ:IRON), recently executed a series of stock transactions amounting to $21,750 in sales. The moves were carried out under a Rule 10b5-1 trading plan adopted in March 2026, following a concurrent acquisition of shares at a significantly lower price point. This activity occurs …
Guardant Health, Inc. (NASDAQ:GH) Chief Information Officer Kumud Kalia has executed a series of stock transactions involving the company’s common equity. The filings detail both sales and purchases of shares at prices hovering around the $130 mark. These personal trading activities occur against a backdrop of significant regulatory developments an…
Kymera Therapeutics, Inc. (NASDAQ:KYMR) director Bruce Booth facilitated the sale of approximately $3.42 million worth of common stock on June 29, 2026. The transaction involved 31,283 shares executed through two Atlas Venture funds under a Rule 10b5-1 trading plan. The sale occurs as KYMR shares have appreciated significantly over the past year, c…
Jesus Llorca, Executive Vice President and Chief Financial Officer of SEACOR Marine Holdings Inc. (NASDAQ:SMHI), executed the sale of 16,110 shares of company common stock through an automated Rule 10b5-1 trading plan. The transactions, which occurred on June 29 and June 30, 2026, yielded proceeds of $129,346. This executive divestment takes place …
Kymera Therapeutics director Bruce Booth has sold 500,000 shares of the company's common stock, totaling approximately $56.5 million. The transactions, executed through a Rule 10b5-1 trading plan adopted in late 2025, occurred on June 26 and June 29, 2026. This insider activity coincides with significant clinical progress for Kymera Therapeutics, s…
